1st Apr 2015 11:43
WASHINGTON (Alliance News) - Myriad Genetics Inc on Wednesday announced the expansion of its companion diagnostic collaboration with AstraZeneca PLC.
As per terms of the expanded agreement, Myriad's BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza. Lynparza is a PARP or poly-ADP ribose polymerase inhibitor being developed by AstraZeneca.
More than 48,000 people are diagnosed with pancreatic cancer and more than 40,000 will die from the disease each year in the US, the company said.
In December 2014, the US Food and Drug Administration or FDA approved BRACAnalysis CDx to identify ovarian cancer patients with germline mutations in BRCA1/2 who may be appropriate for treatment with Lynparza. The approval of BRACAnalysis CDx was the first time the FDA has approved a complex laboratory developed test or LDT under the premarket approval application process and was the first-ever approval of an LDT companion diagnostic test.
Copyright RTT News/dpa-AFX
Related Shares:
Astrazeneca